This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    nct01954316
Previous Study | Return to List | Next Study

A Study of CFI-400945 Fumarate in Patients With Advanced Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by University Health Network, Toronto
Sponsor:
Collaborators:
Princess Margaret Cancer Foundation
California Institute for Regenerative Medicine
Information provided by (Responsible Party):
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT01954316
First received: September 26, 2013
Last updated: June 16, 2017
Last verified: June 2017
  Purpose

This is a phase 1 study to test different doses of a new investigational drug called CFI-400945 to see which dose is safer in people. This study will also look at the safety of CFI-400945 and to study its effects on patients with advanced cancers. This drug has been tested in animals but not yet in people.

CFI-400945 is an oral (taken by mouth) drug that works by blocking polo-like kinase 4 (PLK4) from working. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to lead to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors growing or shrink them.


Condition Intervention Phase
Advanced Cancer Drug: CFI-400945 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Advanced Cancer

Resource links provided by NLM:


Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • Highest dose level that does not lead to unacceptable toxicity in two or more patients in a dosing group [ Time Frame: From first dose of study drug until the date of unacceptable toxicity, throuhgout the study completion, up to 2 years ]
    Though evaluation of AEs and DLTS of all patients who have received study drug


Secondary Outcome Measures:
  • Pharmacokinetic profile of CFI-400945 fumarate (please see description below) [ Time Frame: Day 1 and Day 28 of Cycle 1 prior to first dose and at 0.5, 1, 2 (± 5 minutes), 4, 6, 8, 10-12 (± 15 minutes), and 24 hours (± 60 minutes) following dosing. Day 1 of Cycle 2 and future cycles, prior to dosing. ]
    • Area under the plasma concentration-time curve (AUC)
    • Elimination half-life (T½)
    • Maximum plasma concentration (Cmax)
    • Minimum plasma concentration (Cmin)
    • Time when Cmax occurs (Tmax)
    • Average plasma concentration at steady state (Cavg)

  • Number of patients with a response to treatment [ Time Frame: through study completion, up to 2 years ]
  • Number of side effects occurring and severity [ Time Frame: through study completion, up to 2 years ]
  • Evaluate the genomic alterations and other molecular features which are associated with response and/or clinical benefit with CFI-400945-CL fumarate treatment [ Time Frame: At any time from when the patient reaches 3 months on trial or more at the time of progression ]
    Through optional tumor biopsy at the time of progression

  • to evaluate pharmacodynamics effects relative to CFI-400945 fumarate at MTD [ Time Frame: At any time from when the patient reaches 3 months on trial or more at the time of progression, up to two years ]
    Through baseline biopsy comparisons with optional tumor biopsy at the time of progression

  • to evaluate intratumoral drug levels of CFI-400945 fumarate at MTD [ Time Frame: At any time from when the patient reaches 3 months on trial or more at the time of progression, up to two years ]
    Through baseline biopsy comparisons with optional tumor biopsy at the time of progression

  • to evaluate possible mechanisms of resistance to CFI-400945 fumarate at MTD [ Time Frame: At any time from when the patient reaches 3 months on trial or more at the time of progression, up to two years ]
    Through baseline biopsy comparisons with optional tumor biopsy at the time of progression


Estimated Enrollment: 48
Study Start Date: March 2014
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CFI-400945 fumarate
CFI-400945 fumarate tablets, dose levels 3, 6, 11, 16, 24, and 32 mg/day
Drug: CFI-400945
Polo-like kinase 4 (PLK4) inhibitor

Detailed Description:

All participants will receive CFI-400945. At the beginning of the study, participants are given a low dose of CFI-400945 and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then more participants are asked to join the study and are given a higher dose of study drug. Participants joining the study later on will get higher doses of study drug than participants who join earlier. This will continue until the highest dose of study drug that can be taken without severe side effects is found (called maximum tolerated dose). Doses higher than that will not be given.

After the best dose of study drug is found, additional participants will be asked to join the study and will be given the study drug at the maximum tolerated dose to further test the safety and the drug at that dose.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have histologic or cytological proof of advanced cancer that has progressed and for which there is no further standard anticancer therapy available in the opinion of the investigator.
  • Patients must have measurable disease as per RECIST v1.1
  • Are 18 years of age or older.
  • Have clinically acceptable laboratory screening results within certain limits
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Able to swallow oral medications.
  • Have a life expectancy greater than 3 months.
  • Women and men of child producing potential must agree to use highly effective means of contraception during study participation, and for at least 30 days after the last administration of study medication.
  • Negative serum pregnancy test with 72 hours prior to start of study drug
  • Have the ability to understand the requirements of the study, provide written informed consent which includes authorization for release of protected health information, abide by the study restrictions, and agree to return for the required assessments.
  • For expansion cohort, patients must consent to provide tissue from newly obtained (during screening period) core or excisional biopsy of a tumor lesion.

Exclusion Criteria:

  • Women who are pregnant or nursing.
  • Have received radiotherapy, chemotherapy, biological therapy or investigational treatment less than four weeks (six weeks for nitrosourea or mitomycin C) prior to first dose of study medication or have not recovered from all acute toxicities from prior treatments.
  • Patients who have received growth factors within 14 days prior to initiation of dosing of CFI-400945 fumarate.
  • Have active, acute, or chronic clinically significant infections.
  • Have uncontrolled severe hypertension
  • Have clinical symptomatic congestive heart failure defined at >= Class II of the New York Heart Association functional classification system or LVEF < 50% at baseline.
  • Have active angina pectoris or recent myocardial infarction (within 6 months).
  • Have chronic atrial fibrillation or QTc of greater than 470 msec, as calculated by Bazett's correction formula.
  • Have had major surgery within 21 days of starting therapy. Placement of a venous access device within 21 days of starting therapy is allowed.
  • Have additional uncontrolled serious medical or psychiatric illness.
  • Have any medical condition that could impair the administration of oral agents including significant bowel resection, inflammatory bowel disease or uncontrolled nausea or vomiting.
  • Known central nervous system metastasis. Patients with history of central nervous system metastases are eligible if they are clinically or radiographically stable for at least 3 months and not taking steroids or anticonvulsants.
  • Patients being treated with full dose warfarin are excluded. Patients with history of deep vein thrombosis or pulmonary embolus who are being treated with therapeutic doses of low molecular weight heparin or prophylactic dose anticoagulants may be enrolled.
  • Patients being treated with certain drugs not acceptable while receiving CFI-400945 fumarate.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01954316

Contacts
Contact: Philippe Bedard, M.D. 416-946-4534

Locations
United States, California
UCLA Medical Center Recruiting
Santa Monica, California, United States, 90404
Contact: Lisa Yonemoto    310-582-4069    lyonemoto@mednet.ucla.edu   
Principal Investigator: Zev Wainberg, MD         
Canada, Ontario
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Philippe Bedard, M.D.    416-946-4534      
Principal Investigator: Philippe Bedard, M.D.         
Sponsors and Collaborators
University Health Network, Toronto
Princess Margaret Cancer Foundation
California Institute for Regenerative Medicine
Investigators
Principal Investigator: Philippe Bedard, M.D. Princess Margaret Cancer Centre
  More Information

Additional Information:
Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT01954316     History of Changes
Other Study ID Numbers: CFI-400945-CL-001
Study First Received: September 26, 2013
Last Updated: June 16, 2017

Keywords provided by University Health Network, Toronto:
advanced cancer
CFI-400945 fumarate
polo-like kinase 4
PLK4
tablet
dose escalation
genetic testing

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on September 19, 2017